Doxorubicin is an anthracycline antibiotic with antineoplastic activity produced by the bacterium Streptomyces peucetius var. Doxorubicin is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis.
Structure of 25316-40-9
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
1 g | $398 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Title | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|---|
NCT00000626 | Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | HIV Infections | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000658 | A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000681 | A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma | Sarcoma, Kaposi | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000689 | Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | Lymphoma, Non-Hodgkin | Phase 1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | |
NCT00000703 | Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members | Lymphoma, Non-Hodgkin | National Institute of Allergy and Infectious Diseases (NIAID) | Completed |
Doxorubicin hydrochloride is an anthracycline antibiotic and a potent ADC cytotoxin widely utilized as an ADC payload in antibody-drug conjugates. Its cytotoxic mechanism involves intercalation into DNA, inhibition of topoisomerase II, and generation of reactive oxygen species (ROS), leading to DNA strand breaks, cell cycle arrest, and induction of apoptosis in proliferating tumor cells. The hydrochloride form enhances solubility and chemical stability, facilitating conjugation to monoclonal antibodies via cleavable or non-cleavable linker chemistries, enabling precise intracellular delivery in ADC applications.
Within antibody-drug conjugates, Doxorubicin hydrochloride is covalently attached to antibodies using linker systems designed to maintain systemic stability and prevent premature payload release. The ADC remains inactive in circulation, reducing off-target cytotoxicity. Upon internalization into antigen-expressing tumor cells via receptor-mediated endocytosis, enzymatic or chemical cleavage releases the active doxorubicin payload. Once liberated, it intercalates into nuclear DNA, inhibits topoisomerase II, and generates ROS, leading to apoptosis. This targeted delivery ensures cytotoxic activity is confined to tumor cells, enhancing the specificity of tumor-targeted therapy.
Applications of Doxorubicin hydrochloride include incorporation into ADCs targeting both hematologic malignancies and solid tumors with defined antigen expression. Its compatibility with various linker chemistries allows optimization of conjugation efficiency, intracellular release kinetics, and pharmacokinetic profiles. Doxorubicin hydrochloride demonstrates reproducible cytotoxic activity in target-expressing tumor cells, supporting the development of ADCs with defined DNA-damaging mechanisms and controlled induction of apoptosis, providing a mechanistically precise approach for antibody-drug conjugate design in targeted cancer therapy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00892 | N-(Iodoacetamido)-Doxorubicin | 114390-30-6 | |
1547491-85-9 | N-([1,1'-biphenyl]-4-yl)-[1,1':3',1''-terphenyl]-4'-amine | 1547491-85-9 | |
BADC-00042 | Daunorubicin | 20830-81-3 | |
BADC-00039 | Doxorubicin | 23214-92-8 | |
BADC-01122 | Doxorubicin-SMCC | 400647-59-8 | |
BADC-00363 | Aldoxorubicin hydrochloride | 480998-12-7 | |
BADC-01412 | MA-PEG4-VC-PAB-DMAE-Doxorubicin | ||
BADC-01462 | N3-PEG4-DYKDDDD-Doxorubicin | ||
BADC-01463 | Azide-PEG4-VC-PAB-Doxorubicin | ||
BADC-01464 | N3-PEG4-YPYDVPDYA-Doxorubicin |
What is Doxorubicin hydrochloride?
Doxorubicin hydrochloride is an anthracycline cytotoxic agent widely used as an ADC payload. It intercalates into DNA, inhibiting topoisomerase II activity, leading to DNA damage and apoptosis in targeted cancer cells when delivered via antibodies.
19/8/2020
Could you explain how Doxorubicin hydrochloride functions in ADCs?
In ADCs, Doxorubicin hydrochloride is delivered selectively to antigen-expressing cells. Once internalized, it intercalates into DNA and inhibits topoisomerase II, inducing cell death while minimizing systemic toxicity.
22/10/2022
We would like to know which linkers are appropriate for Doxorubicin hydrochloride.
Doxorubicin hydrochloride can be conjugated with cleavable linkers responsive to intracellular conditions such as pH or enzymes. This ensures controlled release inside target cells while maintaining stability in circulation.
3/10/2021
What precautions should be taken when handling Doxorubicin hydrochloride?
Handling Doxorubicin hydrochloride requires standard cytotoxic safety measures including protective gloves, lab coats, and containment. These precautions prevent accidental exposure during synthesis, conjugation, and laboratory testing.
6/12/2021
Good afternoon! Is Doxorubicin hydrochloride used in preclinical ADC research?
Yes, Doxorubicin hydrochloride is frequently employed in preclinical ADC studies to assess DNA-targeted cytotoxicity, evaluate linker stability, and determine the selective delivery efficiency of antibody conjugates.
16/9/2022
— Dr. Jason Carter, Senior Scientist (USA)
Doxorubicin hydrochloride delivered by BOC Sciences had excellent purity, critical for our conjugation protocols.
3/10/2021
— Dr. Andrew Scott, Oncology Researcher (USA)
Doxorubicin hydrochloride from BOC Sciences was delivered with high purity and proper documentation, essential for ADC development.
16/9/2022
— Ms. Sophie Wagner, Senior Scientist (Germany)
Batch consistency and excellent analytical data for Doxorubicin hydrochloride enabled seamless conjugation studies.
6/12/2021
— Dr. Richard Evans, Biopharmaceutical Scientist (UK)
We achieved reproducible results in all assays using Doxorubicin hydrochloride, reflecting its high-quality manufacture.
19/8/2020
— Mr. Marc Lefevre, ADC Development Specialist (France)
BOC Sciences provided responsive support and timely delivery for Doxorubicin hydrochloride, helping meet project deadlines.
— Dr. Emma Larsen, Laboratory Head (Denmark)
Reliable sourcing and quality of Doxorubicin hydrochloride allowed us to accelerate our ADC research programs.
22/10/2022
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.